Navigation Links
New therapeutic options for newly diagnosed multiple myeloma patients

ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy. The findings were reported by Craig B. Reeder, M.D., at the American Society of Hematologys annual meeting.

For newly diagnosed multiple myeloma patients, this new treatment provides a more frequent, rapid and deeper response when compared to earlier treatment options, says Dr. Reeder, a Mayo Clinic Cancer Center hematologist/oncologist and lead investigator of the study. This is the first time we have studied this treatment in newly diagnosed patients with this condition. Compared with past therapies, this new treatment proved to be very successful.

The team studied 30 patients receiving Cybor-D in the trial. As a relevant contemporaneous control for speed and depth of response, researchers compared 34 patients treated on a recent Mayo Clinic trial of L-Dex. The findings showed that Cybor-D produced a rapid initial decline and percentage reduction in M protein (abnormal protein present in blood of myeloma patients) and a significantly higher rate of good or complete responses than L-Dex. Prophylactic use of acyclovir, a quinolone and antifungal prophylaxis was highly recommended for all patients on the study.


Contact: Jenny Ho
Mayo Clinic

Page: 1

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: